Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective e...
Genentech, a member of the Roche Group, announced that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...
Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oli...
Roche announced that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OC...
Shanghai Yingli Pharmaceutical Co., Ltd., a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune dis...
Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecule dru...
Bavarian Nordic A/S announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox and...
Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced moderated poster presentations of new data from the landmark HELIOS-B...
TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a...
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Un...
Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with pro...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. D...
© 2025 Biopharma Boardroom. All Rights Reserved.
